Endometrial Cancer Clinical Trials in Columbus, Ohio

16 studies are recruiting for endometrial cancer in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cel…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus, Ohio
    Locations
    264 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06952504 on ClinicalTrials.gov

  2. Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

    This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University Comprehensive, Columbus, Ohio
    Locations
    121 in total
    Run by
    Canadian Cancer Trials Group

    See if you can join NCT05640999 on ClinicalTrials.gov

  3. Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

    The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Ohio State University Wexner Medical Center, Columbus, Ohio
    Locations
    53 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT03564340 on ClinicalTrials.gov

  4. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participant…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Columbus, Ohio
    Locations
    255 in total
    Run by
    AstraZeneca

    See if you can join NCT06989112 on ClinicalTrials.gov

  5. Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

    The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

    Stage
    Phase 1
    Ages
    15 and older
    Site
    The Ohio State University, Columbus, Ohio
    Locations
    22 in total
    Run by
    Xencor, Inc.

    See if you can join NCT06276491 on ClinicalTrials.gov

  6. Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

    This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

    Stage
    Phase 1
    Ages
    18 to 130
    Site
    Research Site, Columbus, Ohio
    Locations
    60 in total
    Run by
    AstraZeneca

    See if you can join NCT05797168 on ClinicalTrials.gov

  7. A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

    This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Ohio State University Wexner Medical Center, Columbus, Ohio
    Locations
    28 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT04590326 on ClinicalTrials.gov

  8. A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

    HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Wexner Medical Center, Columbus, Ohio
    Locations
    12 in total
    Run by
    Whitehawk Therapeutics, Inc.

    See if you can join NCT07470853 on ClinicalTrials.gov

  9. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

    Stage
    Phase 2
    Ages
    18 to 130
    Site
    Research Site, Columbus, Ohio
    Locations
    96 in total
    Run by
    AstraZeneca

    See if you can join NCT05489211 on ClinicalTrials.gov

  10. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus, Ohio
    Locations
    66 in total
    Run by
    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

  11. Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

    This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following pla…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Columbus, Ohio
    Locations
    320 in total
    Run by
    AstraZeneca

    See if you can join NCT07044336 on ClinicalTrials.gov

  12. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  13. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    6 in total
    Run by
    Tanabe Pharma America, Inc.

    See if you can join NCT06943521 on ClinicalTrials.gov

  14. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Columbus, Ohio
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  15. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage
    Not phased
    Ages
    18 and older
    Site
    The Ohio State University Wexner Medical Center, Columbus, Ohio
    Locations
    7 in total
    Run by
    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov

  16. Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

    This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    OhioHealth Institute, Columbus, Ohio
    Locations
    83 in total
    Run by
    Kartos Therapeutics, Inc.

    See if you can join NCT05797831 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.